Pfizer

Stories 21 - 40 | << Prev   Next >>

Slumping Health, Tech Stocks Drag S&amp;P 500 Down
Pfizer Stock Drops
for 2nd Day in a Row
MARKETS
Jan 4, 2022 3:51 PM CST

Pfizer Stock Drops for 2nd Day in a Row

Health, tech stocks dragged down S&P 500 but Dow hit a new record high

(Newser) - Slumping technology stocks left the S&P 500 slightly lower on Wall Street Tuesday, even as the Dow Jones Industrial Average of 30 blue-chip companies marked another record high. Microsoft, Apple, and major chipmakers like Nvidia sank while banks and other sectors rose. Bond yields continued to climb. The yield...

FDA: Fine to Get Booster After Just 5 Months

It also now recommends boosters for kids 12 to 15

(Newser) - The US is expanding COVID-19 boosters as it confronts the omicron surge, with the FDA allowing extra Pfizer shots for children as young as 12. Boosters already are recommended for everyone 16 and older, and federal regulators on Monday decided they're also warranted for 12- to 15-year-olds once enough...

Pfizer Asks US Officials to OK COVID Pill
FDA Approves First COVID Pill
UPDATED
Dec 22, 2021 12:47 PM CST

FDA Approves First COVID Pill

Regulators call Pfizer's Paxlovid pill a 'major step forward' in fight against pandemic

(Newser) - Update: The FDA has approved the first pill to treat COVID-19 at home—and not a moment too soon. Pfizer's Paxlovid antiviral pill was initially seen as an extra drug in the anti-COVID arsenal, but with cases surging and antibody treatments not working against the omicron variant, the pills...

Good News on Moderna Booster
Good
News on
Moderna
Booster
Dec 20, 2021 8:33 AM CST

Good News on Moderna Booster

Early lab results suggests third shot provides significant protection against omicron

(Newser) - Lab results from Moderna add to health officials' chorus on omicron: Get a booster. The company said Monday that preliminary results suggests a third shot of its vaccine provides significant protection against the new variant. The usual half-dose booster raised antibody levels 37-fold, while a full-dose booster—typically given to...

CDC Panel Backs Other Vaccines Over J&amp;J&#39;s
CDC:
Get Pfizer or
Moderna,
Not J&J
UPDATED
Dec 17, 2021 2:51 AM CST

CDC: Get Pfizer or Moderna, Not J&J

CDC makes official new recommendation

(Newser) - Update: The CDC is now officially taking the stance that that "mRNA vaccines are preferred over [Johnson & Johnson's] Janssen COVID-19 vaccine for the prevention of COVID-19 for those 18 years of age and over." Within hours of a panel making that recommendation, the CDC director accepted...

FDA Approves Boosters for Some Teens

Specifically, those aged 16 and 17; CDC decision is pending

(Newser) - The US is expanding COVID-19 boosters, ruling that 16- and 17-year-olds can get a third dose of Pfizer’s vaccine, per the AP . The US and many other nations already were urging adults to get booster shots to pump up immunity that can wane months after vaccination, calls that intensified...

Here's How Pfizer's Vaccine Fares Against Omicron

3 doses 'offer a sufficient level of protection from disease of any severity'

(Newser) - Two doses of the Pfizer/BioNTech coronavirus vaccine may be enough to prevent serious illness with the omicron variant, but may not be enough to prevent an infection, the companies said Wednesday. However, "preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 vaccine neutralize the omicron variant,"...

BioNTech Founder: Omicron Unlikely to Cause Severe Cases

Ugur Sahin says vaccinated people should have protection against new variant

(Newser) - The seesawing of sentiment on the omicron variant continues. The co-founder of BioNTech, the company that partnered with Pfizer on a COVID vaccine, has weighed in with comments that are relatively optimistic. Ugur Sahin tells the Wall Street Journal that the company's existing vaccine should prevent serious illness among...

One Potential COVID Treatment Not as Potent as Hoped

Merck's pill, awaiting FDA review, is less effective than preliminary tests suggested

(Newser) - The COVID virus keeps mutating , and drugmakers are racing to adapt along with it. But on that front, Merck reported some relatively disappointing news about a pill under development—molnupiravir turns out to be 30% effective at reducing hospitalizations and deaths, which is down from preliminary estimates of 50%, reports...

FDA Wants FOI Request on Vaccine to Wait—for 55 Years

Experts want to see information used in approving Pfizer's product

(Newser) - The experts who have filed a Freedom of Information request to see government data on the Pfizer COVID-19 vaccine might have to hand the issue down to the next generation—at least—of scientists and professors. The Food and Drug Administration has asked a judge to not force the documents'...

Kids 5-11 Getting Vaccinated 3 Times Faster Than Adults Did

White House says 10% of kids now have had shots

(Newser) - The White House says about 10% of eligible kids aged 5 to 11 have received a dose of the Pfizer COVID-19 vaccine since its approval for their age group two weeks ago. At least 2.6 million kids have received a shot, White House COVID-19 coordinator Jeff Zients said Wednesday,...

Deal Will Bring Pfizer's COVID Pill to Half the World

Drug-maker will let others make the pill so it can be sold cheaply in poorer countries

(Newser) - Pfizer is teaming up with Medicines Patent Pool, a nonprofit based in Geneva and backed by the UN, to bring its new COVID pill to poorer countries. They’ll work with about a dozen manufacturers of generic drugs to bring affordable access to the pill, once it's approved, to...

2 More Conglomerates Are Breaking Up

J&J, Toshiba announce plans to separate their businesses in coming years

(Newser) - Johnson & Johnson plans to split into two publicly traded companies. And in case you're wondering, no, they won't be called "Johnson I" and "Johnson II." Johnson & Johnson will keep its name and its title as the world's largest health-products company by sales...

Pfizer: New Study Makes Case for Booster Shots for All Adults

FDA says it will review application 'as expeditiously as possible'

(Newser) - Pfizer asked US regulators Tuesday to allow boosters of its COVID-19 vaccine for anyone 18 or older, a step that comes amid concern about increased spread of the coronavirus with holiday travel and gatherings. Older Americans and other groups particularly vulnerable to the virus have had access to a third...

Pfizer: COVID Pill Results Are Beyond Our 'Wildest Dreams'

'Game-changer' cuts risk of hospitalization or death by 89%, company says

(Newser) - Pfizer execs say a clinical trial of a COVID-19 pill has succeeded beyond their "wildest dreams." The company says the antiviral pill, which it plans to sell under the brand name Paxlovid, cut the risk of hospitalization or death among high-risk patients by 89% when it was taken...

Kids as Young as 5 May Get Shots Next Week

FDA backs Pfizer shots for children, with final details to emerge next week

(Newser) - The Food and Drug Administration on Friday paved the way for children ages 5 to 11 to get Pfizer's COVID-19 vaccine. The FDA cleared kid-size doses—just a third of the amount given to teens and adults—for emergency use, and up to 28 million more American children could...

FDA Panel Endorses COVID Shots for Kids

Vote was 17-0, with one abstention

(Newser) - The Biden administration has vaccines ready to roll for millions of children ages 5 to 11—and the plan cleared another hurdle Tuesday when a Food and Drug Administration panel endorsed the child-size doses of the Pfizer-BioNTech coronavirus vaccine. The panel of independent vaccine advisers voted 17-0 in favor of...

WH Has Vaccines Ready to Roll for Kids 5-11

Biden administration unveils plan for inoculating younger children once FDA, CDC give OK

(Newser) - "Another major milestone" is on the horizon in the fight against COVID, and this time it centers on some of our youngest Americans. CNN reports that the Biden administration has enough vaccine doses for the 28 million children in the US who are ages 5 to 11, as a...

Deaths Spike as OD Antidote Price Soars

Expert attributes thousands of deaths to greed amid naxolone supply issues

(Newser) - The US has seen a record high in overdose deaths during the pandemic, and an addiction expert says "we can expect even more fatal overdoses" now that a medication that reverses overdoses has jumped up to 30 times in price. The Opioid Safety and Naloxone Network Buyers Club, a...

J&J Could've Been 2 Shots All Along, Fauci Says

Booster recipients probably will be able to mix brands

(Newser) - In hindsight, the Johnson & Johnson coronavirus vaccine probably should have been two shots from the start, as other vaccines are, Dr. Anthony Fauci said Sunday. Asked on ABC's This Week whether people who received the company's single dose should be alarmed because an FDA advisory panel has...

Stories 21 - 40 | << Prev   Next >>
Most Read on Newser